Henan Lingrui Pharmaceutical plans to acquire Silver Valley Pharmaceutical for 0.782 billion, entering the market of traditional Chinese medicine plaster agents as a leading player in crossover pharmaceutical markets. | Quick summary announcement.

① Henan Lingrui Pharmaceutical plans to acquire all equity of Yingu Pharmaceutical for 0.782 billion yuan, entering the chemical and innovative drugs market. ② According to data from MoShang Pharmaceuticals, Yingu Pharmaceutical's sales exceeded 0.4 billion yuan in 2023, with the top-selling product being Jin'erli, accounting for about 70% of the company's total revenue, and the growth rate of the Class 1 new drug Bilitin is relatively fast. ③ If the acquisition of Yingu Pharmaceutical proceeds smoothly, the difficulty of achieving the previously set stock-based incentive unlock goals may be significantly reduced.

cls.cnDec 4 23:07

Henan Lingrui Pharmaceutical disclosed a stock-based incentive plan. Unlocking conditions: annual average double-digit growth in non-net income. | Speed read announcement

Henan Lingrui Pharmaceutical has announced a new round of restricted stock incentive plan and employee stock ownership plan, with slightly lowered performance assessment targets compared to the previous incentive plan, but still maintaining double-digit non-GAAP performance assessment requirements. In addition to Henan Lingrui Pharmaceutical, Tibet Cheezheng Tibetan Medicine has also announced an employee stock ownership plan with high performance targets, and the industry expects bone health to be a high-potential product category in the outpatient market.

cls.cnNov 29 23:25

Tasly Pharmaceutical Group: Some products price reduction led to a decline in Q3 gross margin. All parties are actively promoting the trade with China Resources Sanjiu Medical & Pharmaceutical | Focus on earnings conference

① Affected by the overall low prosperity of the pharmacy industry, the company's pharmaceutical commerce sector saw a decline in revenue in the third quarter this year; the pharmaceutical industry sector's revenue grew year-on-year, but price reductions on some products led to a decrease in gross margin, and the company expects the gross margin to remain stable in the future. ② Regarding the equity trade matters between the company's major shareholder and china resources sanjiu medical & pharmaceutical, the company's general manager Cai Jinyong stated that the company and relevant parties are actively promoting various works for this transaction.

cls.cnNov 27 22:29

Involving 5 listed companies! The 'C-class' sanitary napkin is suspected of being unhygienic. The product inspection report reveals the truth.

① The topic of "Category C sanitary napkins" continues to ferment, with controversy focusing on pH value and formaldehyde content; ② Reporters obtained inspection reports from eight sanitary napkin brands, most of which can reach Category A; ③ Category A and C are textile standards, but indicators like pH value are also adopted in sanitary napkins; ④ It is precisely based on the pH value and formaldehyde indicators that netizens question whether the sanitary napkin standards only reach Category C.

cls.cnNov 21 21:39

Aimer Group: Cost reduction and efficiency improvement cannot stop the decline in demand. The end of the third quarter is a conventional high point for inventory｜Directly hitting the earnings conference.

① Aimer Co., Ltd. stated at the earnings conference that the end of the third quarter is a relative high point of inventory in the company's regular operation, mainly for stocking up for the sales peak in the fourth quarter; ② The main reason for the loss in the third quarter is the significant drop in market demand, and the company's revenue decline is substantial, while the efforts to increase efficiency and reduce costs could not offset the impact of the revenue decrease; ③ The company's sportswear sector is still in its infancy, and its contribution to performance is not significant.

cls.cnNov 19 17:05

Significant asset restructuring changes, jinfa labi maternity & baby articles plans to reduce the acquisition of symbol equity to 51% | Quick read announcement.

① Jinfa Labi has terminated the major assets restructuring and changed to acquiring 51% equity of Zhuhai Hanfei and Zhongshan Hanfei, which does not constitute a major assets restructuring. ② Jinfa Labi has reported net income losses for two consecutive years, with revenue of 0.139 billion yuan in the first three quarters, a year-on-year decline of 7.63%, and a net income of -9.9525 million yuan attributable to shareholders.

cls.cnNov 17 21:46